Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)

Phase II Study of Nanocurcumin Versus Placebo for Patients Undergoing Radiotherapy for Prostate Cancer

There is a growing body of evidence exploring the role of curcumin as a radioprotector against radiation-induced injury in normal tissues as well as a radiosensitizer in tumor cells. The aim of this study is to determine the efficacy of oral nanocurcumin in prostate cancer patients undergoing radiotherapy.

Inclusion Criteria:

• Histologically confirmed adenocarcinoma of the prostate
• Candidate for External Beam Radiotherapy
• ECOG performance status 0-2

Exclusion Criteria:

• Patients with Metastatic Prostate Cancer
• Patients with Kidney & Liver dysfunction
• Gastrointestinal disorders such as IBD, reflux and peptic ulcers
• Any adverse reaction to curcumin